Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell Mobilization

Table 1

Baseline characteristics and mobilization outcomes (𝑁=16).

Median age in years (range)	56 (20–71)
Gender	56% male
Race	63% Caucasian
	37% African American
Disease subtypes	37% non-Hodgkin lymphoma
	44% multiple myeloma
	19% others^1
Mobilization chemotherapy regimens	69% cyclophosphamide^2
	31% others^3
Disease status at the time of transplant	37% complete remission
	37% partial remission
	13% stable disease
	13% progressive disease
Median number of prior therapies (range)	2 (1–3)
Prior radiation therapy	19%
Median number of days of G-CSF administration after chemotherapy prior to the administration of plerixafor (range)	12 (7–21)
Median number of days to plerixafor administration after chemotherapy (range)	16 (12–25)
Mean white blood cell count (/𝜇L) at the time of starting plerixafor Therapy (range)	13.4 (4.1–25.2)
Mean absolute neutrophil count (/𝜇L) at the time of starting plerixafor Therapy (range)	11.7 (3.5–20.7)
Median peripheral blood CD34+ cell count (/𝜇L) at the time of starting plerixafor therapy (range)	3.5 (0–15)
Median peripheral blood CD34+ cell count (/𝜇L) at the time of starting apheresis (range)	8.5 (2–30)
Median number of plerixafor doses (range)	2 (1–8)
Median number of apheresis sessions (range)	3.5 (2–7)
Median number of CD34+ cells (×10^6 cells/kg) collected prior to starting plerixafor (range)	0 (0–3.13)
Median number of CD34+ cells (×10^6 cells/kg)collected	3.9 (2.4–7.8)
Percentage of patients with >2 × 10^6 cells/kg CD34+ cells collected	100%
Percentage of patients with >5 × 10^6 cells/kg CD34+ cells collected	19% (3/16)
Median increase in CD34+ cell count (/𝜇L) after first dose of plerixafor (range)	6.5 (1–35)

¹Other diagnoses included Hodgkin lymphoma = 2 and Ewing sarcoma = 1.
²Cyclophosphamide dose = 3-4 gm/m² intravenously.
³Other chemotherapies included ICE (ifosfamide, carboplatin and etoposide), Hyper-CVAD (cyclophosphamide, vincristine, doxorubicin and dexamethasone), and D-PACE (dexamethasone, cisplatin, doxorubicin, cyclophosphamide, and etoposide).